Franck Monnien

Dr. Franck Monnien

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2012 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
FVFranck Vitte
Franck Vitte
BFBettina Fabiani
Bettina Fabiani
CBClaire Bénet
Claire Bénet
SDSophie Dalac
Sophie Dalac
BBBrigitte Balme
Brigitte Balme
TPTony Petrella
Tony Petrella
Chronic myelomonocytic leukemia (CMML) is a rare clonal hematopoietic disorder that can also involve the skin. The histopathology of these skin lesions is not clearly defined, and few data are available in the literature. To better understand tumoral skin involvements in CMML we carried out an extensive, retrospective clinicopathologic study of 42 cases selected from the database of the French Study Group of Cutaneous Lymphomas. On the basis of clinical data, morphology, and phenotype we identified 4 clinicopathologic profiles representing 4 distinct groups. The first group comprised myelomonocytic cell tumors (n=18), exhibiting a proliferation of granulocytic or monocytic blast cells, which were CD68 and/or MPO positive but negative for dendritic cell markers. The second group comprised mature plasmacytoid dendritic cell tumors (n=16), denoted by a proliferation of mature plasmacytoid dendritic cells, which were CD123, TCL1, and CD303 positive but CD56, CD1a, and S100 negative. The third group comprised blastic plasmacytoid dendritic cell tumors (n=4), characterized by a proliferation of monomorphous medium-sized blast cells, which were CD4, CD56, CD123, TCL1 positive but CD1a and S100 negative. The fourth group consisted of a putatively novel category of tumor that we named blastic indeterminate dendritic cell tumors (n=4), distinguished by a proliferation of large blast cells that not only exhibited monocytic markers but also the dendritic markers CD1a and S100. These 4 groups showed distinctive outcomes. Finally, we showed, by fluorescence in situ hybridization analysis, a clonal link between bone marrow disease and skin lesions in 4 patients. Herein, we have described a novel scheme for pathologists and physicians to handle specific lesions in CMML, which correspond to a spectrum of myelomonocytic and dendritic cell proliferations with different outcomes. A minimal panel of immunohistochemical markers including CD68, CD1a, S100, Langerin, and CD123 is necessary to make the correct classification in this spectrum of cutaneous CMML tumors, in which dendritic cell lineage plays an important role.

5 May 2017 in Brain Pathology
Verified
Journal Article
Closed access
PDF file
ATArnault Tauziede‐Espariat
Arnault Tauziede‐Espariat
BPBéatrice Parfait
Béatrice Parfait
ABAurore Besnard
Aurore Besnard
JLJoëlle Lacombe
Joëlle Lacombe
JPJohan Pallud
Johan Pallud
PVPascale Varlet
Pascale Varlet

4 January 2016 in Journal of Neuropathology & Experimental Neurology
Verified
Journal Article
Open access
PDF file
ATArnault Tauziède-Espariat
Arnault Tauziède-Espariat
DBDamien Bresson
Damien Bresson
MPMarc Polivka
Marc Polivka
SBSchahrazed Bouazza
Schahrazed Bouazza
FLFrançois Labrousse
François Labrousse
HAHoma Adle-Biassette
Homa Adle-Biassette
Chordomas are slow-growing malignant neoplasms. Determination of histopathologic prognostic factors using a large cohort study has been limited by their low incidence. In this retrospective study, we investigated the clinical, histopathologic, and immunohistochemical prognostic factors in 287 chordomas from 111 patients assessed by central pathologic review. Expression patterns of a variety of markers, including vascular endothelial growth factor (VEGF), mTOR pathway, c-kit, HER2, epidermal growth factor receptor (EGFR) and STAT3, and KRAS , BRAF, EGFR , and PIK3CA mutations were analyzed. On univariate analysis, the results confirm surgery as the best treatment, as judged by patient progression-free survival (PFS) and overall survival (OS). Proton therapy, the presence of a dedifferentiated component, mitotic figures, and Ki67 and p53 labeling indices correlated with PFS. Necrosis and apoptosis correlated with OS. Based on these findings, we propose a histopathologic grading system that correlates with PFS and OS. On multivariate analysis, extent of resection, tumor grade, and proton therapy were independent prognostic factors of PFS; extent of resection, tumor location, and grade were independent prognostic factors of OS. Based on the expression of EGFR, pSTAT3, VEGF, and mTOR pathway proteins, (in 85.9%, 79.1%, 85.7%, and 46% of chordomas, respectively), and 2 new mutations in the PIK3CA gene, we also provide evidence for potential therapeutic targets.

1 May 2009 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
MFMarie E. Fondrevelle
Marie E. Fondrevelle
BKBernadette Kantelip
Bernadette Kantelip
RRRobert E. Reiter
Robert E. Reiter
DCDominique K. Chopin
Dominique K. Chopin
JTJean P. Thiery
Jean P. Thiery
HWHervé Wallerand
Hervé Wallerand

17 October 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
Eric HervouetEric Hervouet
Eric Hervouet
ACAurore Claude-Taupin
Aurore Claude-Taupin
TGThierry Gauthier
Thierry Gauthier
VPValérie Perez
Valérie Perez
AFAnnick Fraichard
Annick Fraichard
MBMichaël Boyer-Guittaut
Michaël Boyer-Guittaut
The GABARAP family members (GABARAP, GABARAPL1/GEC1 and GABARAPL2 /GATE-16) are involved in the intracellular transport of receptors and the autophagy pathway. We previously reported that GABARAPL1 expression was frequently downregulated in cancer cells while a high GABARAPL1 expression is a good prognosis marker for patients with lymph node-positive breast cancer. In this study, we asked using qRT-PCR, western blotting and epigenetic quantification whether the expression of the GABARAP family was regulated in breast cancer by epigenetic modifications. Our data demonstrated that a specific decrease of GABARAPL1 expression in breast cancers was associated with both DNA methylation and histone deacetylation and that CREB-1 recruitment on GABARAPL1 promoter was required for GABARAPL1 expression. Our work strongly suggests that epigenetic inhibitors and CREB-1 modulators may be used in the future to regulate autophagy in breast cancer cells.

1 June 2013 in Human Pathology
Verified
Journal Article
Closed access
SVSéverine Valmary-Degano
Séverine Valmary-Degano
EJElise Jacquin
Elise Jacquin
JPJean-Luc Prétet
Jean-Luc Prétet
FMFranck Monnien
Franck Monnien
BGBenoit Girardo
Benoit Girardo
CMChristiane Mougin
Christiane Mougin